Overview

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Status:
Recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Respirion Pharmaceuticals Pty Ltd

Treatments:

Tobramycin